Oncología médica
Especialidad
Complexo Hospitalario Universitario da Coruña
La Coruña, EspañaPublikationen in Zusammenarbeit mit Forschern von Complexo Hospitalario Universitario da Coruña (19)
2024
-
BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC
Lung Cancer, Vol. 194
-
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789
2023
-
Immunogenicity of COVID-19 vaccines in lung cancer patients
Lung Cancer, Vol. 184
-
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer
New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513
-
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme
European Journal of Cancer, Vol. 182, pp. 3-14
2022
-
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study
Translational Lung Cancer Research, Vol. 11, Núm. 1, pp. 53-63
2018
-
Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/ HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial a randomized phase 3 clinical trial
JAMA Oncology, Vol. 4, Núm. 3, pp. 302-308
-
Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy
Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1548-1556
2017
2015
-
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
Scientific Reports, Vol. 5
2013
-
Dolor como factor predictor de depresión en el paciente oncológico: estudio de casos y controles. Estudio D-PRESS
Revista de la Sociedad Espanola del Dolor, Vol. 20, Núm. 3, pp. 113-121
2010
-
Adjuvant docetaxel for high-risk, node-negative breast cancer
New England Journal of Medicine, Vol. 363, Núm. 23, pp. 2200-2210
-
Current controversies in the management of breast cancer
Clinical and Translational Oncology, Vol. 12, Núm. 4, pp. 278-286
-
Erratum: Current controversies in the management of breast cancer (Clinical and Translational Oncology 12:4 (278-286))
Clinical and Translational Oncology
-
SEOM clinical guidelines for the treatment of metastatic breast cancer
Clinical and Translational Oncology, Vol. 12, Núm. 11, pp. 719-723
2009
-
Screening for epidermal growth factor receptor mutations in lung cancer
New England Journal of Medicine, Vol. 361, Núm. 10, pp. 958-967
2008
-
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814
2004
-
Single nucleotide polymorphisms and outcome in docetaxel - Cisplatin-treated advanced non-small-cell lung cancer
Annals of Oncology, Vol. 15, Núm. 8, pp. 1194-1203
2003
-
Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer
Lung Cancer, Vol. 39, Núm. 1, pp. 77-84